Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma.
MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.
Company Details
- Employees
- 22
- Founded
- 2000
- Address
- 1 Caspian Point, Caspian Way,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- midatechgroup.com
- HQ
- Cardiff, Cardiff
Biodexa Pharmaceuticals Plc Questions
Biodexa Pharmaceuticals Plc's website is midatechgroup.com
Biodexa Pharmaceuticals Plc's LinkedIn profile is https://uk.linkedin.com/company/biodexa
Biodexa Pharmaceuticals Plc has
22 employees.
View email and phone details for 22
employees at Biodexa Pharmaceuticals Plc.
Biodexa Pharmaceuticals Plc's industry is
Biotechnology Research
Biodexa Pharmaceuticals Plc's top competitors are
Oxb,
Emtora Biosciences,
Incyte,
Vivebiotech,
Mikrobiomik,
Tonix Pharmaceuticals,
Aavantgarde,
Faes Farma,
Pfizer,
Precision For Medicine.
Biodexa Pharmaceuticals Plc's categories are Biotechnology Research
Biodexa Pharmaceuticals Plc's founding year is 2000
